恒瑞医药 01276 Stock Information

// Company Overview //

Stock Name	恒瑞医药
Stock Code	01276
Company Full Name	恒瑞医药
Industry	醫療保健
Principal Activities	公司是一家根植中國、全球領先的創新型制藥企業，聚焦腫瘤、代謝和心血管疾病、免疫和呼吸系統疾病以及神經科學等領域進行新藥研發，是國內最具創新能力的制藥龍頭企業之一。
Listing Date	2025-05-23
Listing Rules Era	Old Rules
Listing Rules Chapter	No data
Weighted Voting Rights (WVR)	No
Registered Address (Mainland China)	中國江蘇省連云港市經濟技術開發區昆侖山路7號
Business Address (Hong Kong)	No data
Place of Incorporation	No data
Listing Method	No data
Listing Board	Main Board
Website	https://www.hengrui.com/
Share Registrar	卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact	(852)2980 1333
A-Share/US Dual Listing	No data

// Offering Information //

Offering Mechanism	机制B
Clawback Tiers	机制B不设回拨，公开发售占比维持21.5%
Prospectus Date	2025-05-15
Offer Price	HK$ 44.05 / shares
Offer Price Range	Final offer price only, no range
Lot Size	200 shares
Entry Threshold	HK$ 8,810
Par Value	No data
Global Offering Shares	224,519,800
HK Public Offering Shares	48,271,800 (21.5%)
International Placing Shares	— (0.0%)
Offer Ratio	No data
Total Shares Post-IPO	No data
Total Global Offering Size	HK$ 9,890,097,190
Public Offering Size	HK$ 2,126,372,790 (21.5%)
Oversubscription Multiple	454.9x
Valid Applications	203,874
Accepted Applications	92,430
Reallocation	No
Total Funds Raised	HK$ 2,126,372,790
Greenshoe (Over-allotment Option)	No data
Final Public Offering Share	21.5%

// Valuation & Financials //

Market Cap (at Offer Price)	HK$ 0
Pre-IPO Valuation (Last Round)	No data
P/E Ratio	43.03
Profit/Loss Status	No data
Period-End Cash Balance	No data
Listing Expenses	~HK$ 142,800,000
Listing Expenses / Funds Raised	No data
Total Pre-IPO Investment	No data

// First Day Performance

// Price Chart //

// Use of Proceeds

Use of Proceeds	1、約75%或7,093.4百萬港元將用于研發計劃； 2、約15%或1,418.7百萬港元將用于在中國和海外市場建設新的生產和研發設施； 3、約10%或945.8百萬港元將用作營運資金及其他一般企業用途。

// Underwriting Syndicate //

联席保荐人 (3)

摩根士丹利亚洲有限公司花旗环球金融亚洲有限公司华泰金融控股（香港）有限公司

整体协调人 (4)

摩根士丹利亚洲有限公司花旗环球金融亚洲有限公司华泰金融控股（香港）有限公司瑞银证券香港有限公司

联席账簿管理人 (7)

摩根士丹利亚洲有限公司花旗环球金融亚洲有限公司华泰金融控股（香港）有限公司瑞银证券香港有限公司中银国际亚洲有限公司中信里昂证券有限公司广发证券(香港)经纪有限公司

联席牵头经办人 (7)

// Cornerstone Investors // Allotment Results Announcement

#	Investor Name	Shares Subscribed	% of Offer Shares	% of Total Shares	Lock-up Period	Est. Unlock Date
1	GICPrivateLimited	47,150,800	21.00%	0.71%	2025-11-22	2025-11-22
2	InvescoAdvisers,Inc.	13,195,200	5.88%	0.20%	2025-11-22	2025-11-22
3	Management, L.P.	3,518,600	1.57%	0.05%	—	—

// Directors & Management //

Chairman	孫飄揚
Company Secretary	劉笑含,梁頴嫻

No director data available.

// Major Shareholders //

Major Shareholders & Holdings	江蘇恒瑞醫藥集團有限公司(23.3%),西藏達遠企業管理有限公司(14.4%)

// Allotment Benchmarks //

Pool A (Small Subscriptions)

Shares Applied	Applicants	Allottees	Expected Lots
200	56,065	5,607	0.10
400	17,734	2,590	0.15
600	9,873	1,859	0.19
800	4,464	992	0.22
1,000	9,642	2,435	0.25
1,200	3,250	912	0.28
1,400	1,925	590	0.31
1,600	1,805	598	0.33
1,800	1,762	625	0.35
2,000	15,938	5,998	0.38
3,000	7,169	3,408	0.48
4,000	6,420	3,601	0.56
5,000	4,847	3,091	0.64
6,000	5,637	3,941	0.70
7,000	2,542	1,940	0.76
8,000	2,527	2,113	0.84
9,000	1,870	1,726	0.92
10,000	13,673	13,673	1.00
20,000	7,147	2,975	1.42
30,000	3,921	3,092	1.78
40,000	2,738	2,738	2.00
50,000	2,224	890	2.40
60,000	1,805	1,202	2.67
70,000	1,059	891	2.84
80,000	950	950	3.00
90,000	693	182	3.29
100,000	6,741	3,877	3.60

Pool B (Large Subscriptions)

Shares Applied	Applicants	Allottees	Expected Lots
200,000	5,973	5,973	7.00
300,000	1,169	229	10.20
400,000	671	242	13.40
500,000	431	194	16.50
600,000	262	116	19.50
700,000	127	42	22.40
800,000	97	97	25.20
900,000	67	31	27.45
1,000,000	363	363	30.00
2,000,000	131	131	59.00
3,000,000	59	59	85.50
4,000,000	33	33	112.00
5,000,000	15	15	137.50
6,174,200	55	55	166.70

Allotment Benchmarks

恒瑞医药 01276Stock Information